|
|
|
|
|
|
|
M T W Th Fri |
|
10 July, 2026 |
|
|
sponsored by
|
|
|
|
Katalyze raises $10.5M as five of the top twenty global pharma companies run its agents in production
|
| Deviation and OOS investigations stall because the answers sit fragmented across Veeva, SAP, historians, and paper. Built with more than a hundred tenured scientists from companies including Sanofi, Pfizer, and Lilly, Katalyze grounds its agents in an Operational Data Layer, so every answer traces to a source, and deploys into existing GxP systems with no change to architecture. Customer teams have cut deviation investigations by 50%, lifted throughput 25%, and helped deliver more than 10 million doses to patients. |
|
|
|
|
|
|
|
|
|
|
|
|
|
It's that time of year again: Earnings season is upon us. We'll be keeping a sharp eye on second-quarter results from all the big names, starting with Johnson & Johnson in its customary leadoff spot on July 15. Have a great weekend! |
|
|
|
Alex Hoffman |
Copy Chief and News Editor, Endpoints News
|
|
|
|
|
|
|
by Ayisha Sharma
|
Germany’s federal parliament has voted to pass a bill designed to cut domestic healthcare spending that could negatively impact drugmakers, drawing sharp criticism from the... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
MONTREAL— After Novo Nordisk closed its cell therapy unit, Cellular Intelligence contracted neurologist and drug developer Nuno Mendonça to conduct due diligence on the... | |
|
|
|
 |
|
|
|
by Alex Hoffman, Kyle LaHucik, Andrew Dunn
|
→ Danna Breen has been promoted to head of obesity discovery at Pfizer, according to a LinkedIn post. Breen succeeds Kendra Benceand... | |
|
|
|
|
|
|
by Lei Lei Wu
|
After more than a decade of work and plenty of ups and downs, Roche has dropped its Huntington’s disease drug tominersen. The decision comes after... | |
|
|
|
|
|
